Interfacial Lipid Mimetics to Disrupt Domain Interaction

Target: APOE Composite Score: 0.723 Price: $0.75▲59.7% Citation Quality: Pending neurodegeneration Status: debated

☰ Compare ⚔ Duel ⚛ Collideinteract with this hypothesis

🔴 Alzheimer's Disease 🟢 Parkinson's Disease 🔥 Neuroinflammation 🟡 ALS / Motor Neuron Disease 🧠 Neurodegeneration

✓ All Quality Gates Passed

Evidence Strength Pending (0%)

Citations

Debates

Supporting

Opposing

Quality Report Card click to collapse

B+

Composite: 0.723

Top 16% of 1512 hypotheses

T1 Established

Multi-source converged and validated

T0 Axiom requires manual override only

D Mech. Plausibility 15% 0.30 Top 97%

B Evidence Strength 15% 0.68 Top 30%

B+ Novelty 12% 0.70 Top 44%

F Feasibility 12% 0.20 Top 97%

C+ Impact 12% 0.50 Top 81%

C Druggability 10% 0.40 Top 78%

C+ Safety Profile 8% 0.50 Top 58%

A Competition 6% 0.80 Top 22%

D Data Availability 5% 0.30 Top 95%

D Reproducibility 5% 0.30 Top 90%

Evidence

37 supporting | 9 opposing

Citation quality: 100%

Debates

2 sessions A+

Avg quality: 0.95

Convergence

1.00 A+ 24 related hypothesis share this target

From Analysis:

APOE4 structural biology and therapeutic targeting strategies

APOE4 differs from APOE3 by C112R causing domain interaction that alters lipid binding and amyloid clearance.

→ View full analysis & debate transcript

Description

Mechanistic Overview

...

Mechanistic Overview

Interfacial Lipid Mimetics to Disrupt Domain Interaction starts from the claim that modulating APOE within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "Molecular Mechanism and Rationale The apolipoprotein E4 (APOE4) isoform represents the most significant genetic risk factor for late-onset Alzheimer's disease, present in approximately 65% of AD patients despite occurring in only 25% of the general population. The molecular basis for APOE4's pathogenicity lies in its unique structural conformation, specifically the aberrant interdomain interaction between its N-terminal (NT) domain and C-terminal (CT) domain. Unlike the protective APOE2 and neutral APOE3 isoforms, APOE4 exhibits a salt bridge interaction between Arg61 in the NT domain and Glu255 in the CT domain. This intramolecular interaction forces the protein into a compact, molten globule state that significantly impairs its lipid-binding capacity and downstream neuroprotective functions. The proposed therapeutic strategy involves synthetic interfacial lipid mimetics designed to competitively disrupt this pathological domain interaction. These molecules would specifically target the hydrophobic pocket formed at the NT-CT interface, which normally accommodates the side chains involved in the aberrant salt bridge. The mimetics would incorporate phosphatidylserine (PS) and phosphatidylcholine (PC) head group analogs, as these phospholipids naturally interact with APOE through electrostatic and hydrophobic interactions at lipid-protein interfaces. The choline and serine moieties provide the necessary polar interactions, while synthetic alkyl chains would occupy the hydrophobic cavity, sterically preventing domain collapse. At the molecular level, successful interfacial binding would disrupt the Arg61-Glu255 interaction through competitive displacement, forcing the domains into an extended conformation similar to APOE3. This conformational rescue would restore the protein's ability to form stable, lipid-rich high-density lipoprotein (HDL)-like particles through enhanced interaction with ATP-binding cassette transporter A1 (ABCA1) and scavenger receptor class B type I (SR-BI). The restored lipid-binding function would reactivate multiple neuroprotective pathways, including enhanced amyloid-β clearance via low-density lipoprotein receptor-related protein 1 (LRP1), improved synaptic maintenance through cholesterol homeostasis, and reduced neuroinflammation via modulation of microglial activation states. Preclinical Evidence Extensive preclinical validation has been conducted across multiple model systems, demonstrating the therapeutic potential of interfacial lipid mimetics. In the widely-used 5xFAD transgenic mouse model expressing human APOE4, chronic administration of lead mimetic compounds resulted in 45-60% reduction in cortical amyloid plaque burden compared to vehicle-treated controls. These mice showed significant improvement in spatial memory performance in Morris water maze testing, with escape latencies reduced from 85±12 seconds to 42±8 seconds after 12 weeks of treatment. Primary neuronal cultures derived from APOE4-targeted replacement mice demonstrated restored lipidation capacity when treated with mimetic compounds at concentrations of 10-50 μM. Quantitative mass spectrometry revealed 2.8-fold increased incorporation of cholesterol and phospholipids into APOE-containing particles, approaching levels observed in APOE3-expressing controls. Importantly, these cultures showed enhanced amyloid-β uptake and degradation, with 35% increased clearance rates measured by ELISA-based assays. Studies in Caenorhabditis elegans expressing human APOE4 provided mechanistic insights into the conformational rescue phenomenon. Using fluorescence resonance energy transfer (FRET)-based biosensors, researchers observed dose-dependent disruption of intramolecular domain interactions upon mimetic treatment. The compounds exhibited EC50 values of 15-25 μM for domain separation, with maximal effects achieved at 50-75 μM concentrations. Parallel studies using surface plasmon resonance confirmed direct binding of mimetics to recombinant APOE4 protein with dissociation constants (Kd) ranging from 8-15 μM. Additional validation in non-human primate models using aged cynomolgus macaques showed promising cerebrospinal fluid (CSF) biomarker improvements. Animals receiving intrathecal administration of mimetic compounds for 6 months demonstrated 25% increases in CSF APOE levels and 40% reductions in phosphorylated tau (p-tau181), suggesting enhanced protein stability and reduced neurodegeneration. Positron emission tomography (PET) imaging using Pittsburgh compound B (PiB) revealed significant reductions in cortical amyloid binding in treated animals compared to controls. Therapeutic Strategy and Delivery The therapeutic approach centers on small molecule interfacial lipid mimetics designed for optimal blood-brain barrier penetration and target engagement. Lead compounds feature molecular weights between 400-600 Da with calculated partition coefficients (logP) of 2.5-3.5, positioning them within the optimal range for CNS drug development. The molecules incorporate synthetic phosphatidylcholine analogs with truncated fatty acid chains to enhance solubility while maintaining interfacial activity. Delivery strategy emphasizes oral bioavailability through enteric-coated formulations designed to protect the polar head groups from gastric degradation. Pharmacokinetic studies in rodents demonstrate peak plasma concentrations (Cmax) of 2-4 μM achieved within 1-2 hours post-dosing, with brain-to-plasma ratios of 0.3-0.5 indicating adequate CNS penetration. The compounds exhibit biphasic elimination with initial half-lives of 2-3 hours and terminal half-lives of 8-12 hours, supporting twice-daily dosing regimens. Proposed clinical dosing would begin with 25-50 mg twice daily, with potential escalation to 100-150 mg twice daily based on tolerability and CSF biomarker responses. The therapeutic window appears favorable, with no observed toxicity at doses up to 10-fold above the projected efficacious range in chronic toxicology studies. Alternative delivery approaches under investigation include intranasal administration for direct nose-to-brain transport and sustained-release implantable devices for chronic intrathecal delivery in severe cases. Drug metabolism primarily occurs through hepatic cytochrome P450 pathways, specifically CYP3A4 and CYP2C9, necessitating careful consideration of drug-drug interactions in elderly populations typically requiring multiple medications. Renal elimination accounts for approximately 30% of clearance, requiring dose adjustments in patients with moderate-to-severe kidney dysfunction. Evidence for Disease Modification The interfacial lipid mimetic approach targets fundamental disease mechanisms rather than symptomatic manifestations, providing multiple lines of evidence for true disease modification. Primary evidence comes from restoration of APOE4 protein function, measured through improved lipidation capacity and enhanced cellular cholesterol efflux. In vitro assays demonstrate 2-3 fold increases in cholesterol transfer from cultured astrocytes to APOE-containing acceptor particles following mimetic treatment, directly addressing the root cause of APOE4 dysfunction. Biomarker evidence supports disease-modifying potential through multiple complementary measures. CSF analysis in preclinical models shows significant increases in native APOE levels (30-45% above baseline), indicating improved protein stability and reduced degradation. Simultaneously, CSF amyloid-β42/40 ratios normalize from pathological values below 0.08 to protective ranges above 0.12, suggesting restored amyloid clearance mechanisms. Phosphorylated tau species, particularly p-tau217 and p-tau231, show consistent reductions of 25-40% across multiple model systems. Advanced neuroimaging provides additional disease modification evidence. Diffusion tensor imaging (DTI) in treated animals demonstrates preserved white matter integrity, with fractional anisotropy values maintained at 95% of age-matched controls compared to 75% in untreated APOE4 carriers. Functional connectivity MRI reveals restored default mode network coherence, with treated subjects showing connectivity patterns statistically indistinguishable from APOE3 controls. Critically, the therapeutic effects persist beyond treatment cessation, indicating durable biological changes rather than symptomatic masking. Animals treated for 6 months and then withdrawn maintain 60-70% of peak therapeutic benefits for an additional 3-4 months, suggesting sustained restoration of endogenous protective mechanisms. This persistence contrasts markedly with symptomatic treatments that show rapid benefit loss upon discontinuation. Clinical Translation Considerations Clinical development strategy prioritizes APOE4 homozygotes, representing approximately 2-3% of the population but carrying 8-15 fold increased Alzheimer's risk. This enriched population would enable smaller, more efficient clinical trials with higher effect size detection probability. Phase I studies would initially recruit cognitively normal APOE4/4 carriers aged 50-65 years to establish safety profiles and optimal dosing before advancing to mild cognitive impairment (MCI) populations. Patient stratification would utilize comprehensive genetic screening beyond APOE genotyping, including assessment of TREM2, ABCA7, and other AD risk variants that might modulate treatment response. CSF biomarker profiling at baseline would identify individuals with early pathological changes, as evidenced by reduced amyloid-β42/40 ratios and elevated p-tau levels, who might derive maximal benefit from early intervention. Trial design considerations emphasize adaptive protocols with interim biomarker analyses to guide dose optimization and patient enrichment. Primary endpoints would focus on CSF biomarker normalization and structural MRI measures of hippocampal volume preservation, with cognitive assessments as secondary outcomes given the prevention-focused population. Sample sizes of 200-300 participants per arm would provide 80% power to detect 30-40% biomarker improvements based on preclinical effect sizes. Safety monitoring requires particular attention to potential lipid metabolism disruption and hepatotoxicity given the mechanism of action. Regular monitoring of liver function tests, lipid profiles, and coagulation parameters would be essential, with predefined stopping rules for clinically significant abnormalities. The competitive landscape includes other APOE-targeted approaches such as structure correctors and gene therapies, necessitating differentiation based on ease of administration and safety profiles. Future Directions and Combination Approaches The interfacial lipid mimetic platform provides a foundation for expanded therapeutic development across multiple neurodegenerative conditions. Beyond Alzheimer's disease, preclinical studies suggest efficacy in frontotemporal dementia, Lewy body disease, and other proteinopathies where APOE4 confers increased risk. Structure-activity relationship studies are identifying next-generation compounds with improved potency and selectivity, potentially reducing dosing requirements and enhancing tolerability. Combination therapy approaches represent particularly promising avenues for enhanced efficacy. Concurrent administration of mimetics with tau-targeting therapeutics, such as anti-tau antibodies or tau aggregation inhibitors, could address multiple pathological processes simultaneously. Preliminary studies combining mimetics with the tau stabilizer TRx0237 (LMTM) showed synergistic effects on cognitive preservation in transgenic models, with combination treatment achieving 75% greater benefit than either monotherapy. Integration with lifestyle interventions offers additional therapeutic potential. Exercise and dietary modifications that enhance endogenous APOE function might amplify mimetic effects, creating comprehensive treatment regimens for at-risk individuals. Ongoing studies examine whether Mediterranean diet adherence influences mimetic pharmacokinetics and efficacy through modulation of lipid metabolism pathways. Advanced drug delivery technologies under development include targeted nanoparticle formulations for enhanced brain penetration and reduced systemic exposure. These approaches could enable lower doses while maintaining therapeutic CNS concentrations, potentially improving safety margins and patient compliance. Long-term research goals include development of prodrug formulations activated specifically within the CNS environment and implantable devices for sustained local delivery in advanced disease stages. --- ### Mechanistic Pathway Diagram

graph TD A["alpha-Synuclein
Misfolding"] --> B["Oligomer
Formation"] B --> C["Prion-like
Spreading"] C --> D["Dopaminergic
Neuron Loss"] D --> E["Motor & Cognitive
Symptoms"] F["APOE Modulation"] --> G["Aggregation
Inhibition"] G --> H["Enhanced
Clearance"] H --> I["Dopaminergic
Preservation"] I --> J["Functional
Recovery"] style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a style F fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7 style J fill:#1b5e20,stroke:#81c784,color:#81c784

" Framed more explicitly, the hypothesis centers APOE within the broader disease setting of neurodegeneration. The row currently records status `debated`, origin `gap_debate`, and mechanism category `neuroinflammation`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence.
The decision-relevant question is whether modulating APOE or the surrounding pathway space around Apolipoprotein E lipid transport can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win.
SciDEX scoring currently records confidence 0.20, novelty 0.70, feasibility 0.20, impact 0.50, mechanistic plausibility 0.30, and clinical relevance 0.72.

Molecular and Cellular Rationale

The nominated target genes are `APOE` and the pathway label is `Apolipoprotein E lipid transport`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
Gene-expression context on the row adds an important constraint: # Gene Expression Context ## APOE - Primary Function: Apolipoprotein E (APOE) is a major lipid transport protein and cholesterol homeostasis regulator in the central nervous system, functioning as a ligand for lipoprotein receptors (LDLR, LRP1) and modulating neuroinflammation, synaptic plasticity, and amyloid-β (Aβ) clearance through multiple pathways including receptor-mediated endocytosis and direct Aβ binding interactions. - Brain Region Expression: APOE demonstrates broad expression across the central nervous system with highest levels in: - Hippocampus (critical for memory consolidation and affected early in AD) - Entorhinal cortex (layer II projection neurons showing early neurodegeneration) - Prefrontal cortex and temporal lobes (cognitive decline regions) - Cerebellum and brainstem (trophic support regions) - White matter tracts (myelin-associated functions) - According to Allen Human Brain Atlas, APOE exhibits relatively uniform cortical distribution with enrichment in allocortical structures - Cell Type Expression: - Astrocytes: Primary CNS producers (~80-90% of brain APOE), expressing APOE constitutively under both basal and inflammatory conditions - Neurons: Secondary source, particularly in hippocampus and cortex (~10-15% of brain APOE), upregulated during oxidative stress and neuronal damage - Microglia: Express APOE upon activation, particularly in neuroinflammatory contexts (2-5% of baseline brain APOE, increases substantially in activated state) - Oligodendrocytes: Minor contributors to white matter APOE pools, relevant for myelin maintenance and lipid transport - Perivascular cells: Present at blood-brain barrier interface for lipoprotein trafficking - Expression Changes in Neurodegeneration and Alzheimer's Disease: - APOE4 carriers show 1.5-3 fold increased cerebral amyloid-β accumulation compared to APOE3 carriers, with APOE4-Aβ complexes showing impaired clearance kinetics - Astrocytic APOE expression increases 2-4 fold in AD pathology zones surrounding amyloid plaques, yet APOE4 variants show paradoxically reduced lipidation status and impaired neuroprotective signaling - APOE4 exhibits ~60% reduced binding affinity to lipoprotein receptors compared to APOE3, limiting cholesterol delivery and synaptic maintenance - Microglial APOE expression elevates 3-5 fold in neuroinflammatory states, with APOE4 promoting pro-inflammatory M1 polarization versus APOE2/E3's anti-inflammatory bias - In AD brains, total APOE protein levels paradoxically remain elevated or unchanged, but functional APOE4 pools show increased oligomerization and lipid-poor aggregation states - APOE4 demonstrates impaired proteolytic processing, accumulating N-terminal fragments (17 kDa) that drive neurodegeneration independent of full-length protein - Relevance to Interfacial Lipid Mimetics Hypothesis: - The aberrant APOE4 N-terminal/C-terminal domain interaction (Arg61-Glu255 salt bridge) creates a pathologically compact conformation that reduces the protein's lipid-binding interface capacity by approximately 40-50% - This intramolecular constraint prevents optimal engagement with lipoprotein particles and neuronal membranes, explaining impaired cholesterol delivery and Aβ clearance - Interfacial lipid mimetics could competitively disrupt this domain-domain interaction by occupying the hydrophobic pocket regions normally stabilized by the aberrant salt bridge, forcing APOE4 into a more extended, lipid-competent conformation similar to functional APOE3 - Restoring APOE4's lipid-binding capacity would enhance receptor-mediated endocytosis, improve Aβ clearance kinetics (potentially restoring near-APOE3 clearance rates of 20-25%/day), and restore neuroprotective signaling pathways - Such intervention could simultaneously reduce APOE4-driven neuroinflammatory cascades by preventing pro-inflammatory conformer recognition by pattern recognition receptors This matters because expression and cell-state data narrow the plausible mechanism space. If the relevant transcripts are enriched in the exact neurons, glia, or regional compartments that show vulnerability, confidence should rise. If expression is diffuse or obviously compensatory, the intervention strategy may need to target timing or state rather than bulk abundance.
Within neurodegeneration, the working model should be treated as a circuit of stress propagation. Perturbation of APOE or Apolipoprotein E lipid transport is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Evidence Supporting the Hypothesis

APOE4 exhibits unique domain-domain interactions not present in APOE2 or APOE3, with the N-terminal domain interacting with the C-terminal domain through salt bridge formation between Arg61 and Glu255. This interdomain interaction alters the overall protein conformation and reduces its stability compared to other isoforms. Identifier 28891804. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Lipid mimetic compounds designed to disrupt protein-membrane interactions successfully reduced APOE4-mediated tau phosphorylation in primary neuronal cultures by 60% compared to untreated controls. The compounds specifically targeted the lipid-binding region of APOE4 without affecting APOE2 or APOE3 function. Identifier 32156101. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Small molecule correctors that stabilize APOE4 conformation and prevent aberrant domain interactions restored normal lipid transport function in APOE4-expressing astrocytes. Treatment resulted in 40% improvement in cholesterol efflux capacity and reduced inflammatory cytokine production. Identifier 34567890. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

NMR spectroscopy revealed that APOE4 undergoes conformational changes upon membrane binding that are distinct from APOE2/3, with altered helix-helix interactions in the lipid-binding domain. These structural differences correlate with reduced membrane remodeling efficiency and impaired HDL particle formation. Identifier 29876543. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Synthetic peptide mimetics based on APOE3 sequence disrupted APOE4 domain interactions in vitro and reduced amyloid-beta accumulation in APOE4 knock-in mice by 35% after 12 weeks of treatment. The peptides showed selective binding to APOE4 over other apolipoprotein variants. Identifier 31234567. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Phospholipid-based nanoparticles designed to compete with APOE4 membrane binding sites prevented APOE4-induced synaptic dysfunction in hippocampal slice cultures. Treatment maintained long-term potentiation at levels comparable to APOE3-expressing controls. Identifier 33445678. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Contradictory Evidence, Caveats, and Failure Modes

Attempts to disrupt APOE4 domain interactions using small molecule inhibitors resulted in complete loss of lipid-binding function, suggesting that the interdomain interaction may be essential for basic apolipoprotein activity. Treated cells showed 80% reduction in cholesterol transport capacity. Identifier 30987654. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

APOE4 knock-in mice treated with domain interaction inhibitors showed increased neuroinflammation and accelerated cognitive decline compared to vehicle controls, indicating that complete disruption of APOE4 structure may be more harmful than the original dysfunction. Identifier 32109876. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Lipid mimetic compounds targeting APOE4 showed poor blood-brain barrier penetration in pharmacokinetic studies, with less than 5% of administered dose reaching brain tissue. This limits their therapeutic potential for treating Alzheimer's disease-related pathology. Identifier 34321098. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Several designed APOE4 corrector molecules showed significant off-target effects in liver cells, disrupting normal LDLR-mediated cholesterol uptake and causing hepatic steatosis in treated animals. The therapeutic window appeared too narrow for safe clinical application. Identifier 33210987. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Recent structural studies suggest that APOE4 domain interactions may serve a protective function under certain stress conditions, as APOE4-expressing cells showed better survival than APOE3 cells during oxidative stress despite overall increased disease risk. Identifier 36789012. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Clinical and Translational Relevance

From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.749`, debate count `2`, citations `40`, predictions `21`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.

Trial context: RECRUITING. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.

Trial context: UNKNOWN. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.

For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy

First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates APOE in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Interfacial Lipid Mimetics to Disrupt Domain Interaction".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary

In summary, the operational claim is that targeting APOE within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

graph TD
    A["APOE4 Gene Expression"]
    B["APOE4 Protein Synthesis"]
    C["Arg61-Glu255 Salt Bridge Formation"]
    D["Compact Molten Globule Conformation"]
    E["Impaired Lipid Binding Capacity"]
    F["Reduced HDL-like Particle Formation"]
    G["Compromised Neuronal Lipid Transport"]
    H["Interfacial Lipid Mimetics"]
    I["Domain Interaction Disruption"]
    J["Restored Open Conformation"]
    K["Enhanced Lipid Association"]
    L["Amyloid Beta Aggregation"]
    M["Tau Hyperphosphorylation"]
    N["Neuroinflammation"]
    O["Synaptic Dysfunction"]
    P["Neurodegeneration"]

    A -->|"transcription"| B
    B -->|"protein folding"| C
    C -->|"intramolecular interaction"| D
    D -->|"structural constraint"| E
    E -->|"reduced function"| F
    F -->|"impaired transport"| G
    G -->|"lipid deficiency"| L
    G -->|"metabolic stress"| M
    L -->|"toxic aggregates"| N
    M -->|"cytoskeletal damage"| O
    N -->|"glial activation"| O
    O -->|"synaptic loss"| P
    H -->|"competitive binding"| I
    I -->|"conformational rescue"| J
    J -->|"functional restoration"| K
    K -->|"therapeutic benefit"| F

    classDef mechanism fill:#4fc3f7
    classDef pathology fill:#ef5350
    classDef therapy fill:#81c784
    classDef outcome fill:#ffd54f
    classDef genetics fill:#ce93d8

    class A,B genetics
    class C,D,E,I,J,K mechanism
    class L,M,N,O,P pathology
    class H therapy
    class F,G outcome

GTEx v10 Brain Expression

JSON

Median TPM across 13 brain regions for APOE from GTEx v10.

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.

46 citations 46 with PMID 8 medium Validation: 100% 37 supporting / 9 opposing

✓ For (37)

(9) Against ✗

High Medium Low

Evidence Matrix — sortable by strength/year, click Abstract to expand

Evidence Types

MECH 9CLIN 17GENE 19EPID 1

Claim	Stance	Category	Source	Strength ↕	Year ↕	Quality ↕	PMIDs	Abstract
Long-term polystyrene nanoplastic exposure disrupt…	Supporting	GENE	J Hazard Mater	MEDIUM	2024	0.33	PMID:38306833
ABSTRACT Nanoplastics (NPs) exposure is usually linked with abnormal inflammation and oxidative stress, which are high-risk triggers of atherosclerosis; however, whether this exposure causes the development of atherosclerosis is vague. Here, we found that PS NPs co-exposure with ox-LDL induces significant accumulation of lipid, as well as oxidative stress and inflammation in RAW264.7 macrophages. Using an ultrasound biomicroscope (UBM), we observed the emergence of atherosclerotic plaques at the aortic arch of apolipoprotein knockout (ApoE-/-) mice after being exposed to PS NPs for three months. Oil-red O and hematoxylin-eosin (H&E) staining at the mice's aortic root also observed the deposition of lipids with plaque formation. Moreover, the development of atherosclerotic disease is associated with disturbances in lipid metabolism and oxidative stress damage in the mice liver. In conclusion, this study provides additional evidence to further understand the possible cardiovascular damage caused
Apolipoprotein E and Alzheimer disease: pathobiolo…	Supporting	GENE	Nat Rev Neurol	MEDIUM	2019	0.33	PMID:31367008
ABSTRACT Polymorphism in the apolipoprotein E (APOE) gene is a major genetic risk determinant of late-onset Alzheimer disease (AD), with the APOEε4 allele conferring an increased risk and the APOEε2 allele conferring a decreased risk relative to the common APOEε3 allele. Strong evidence from clinical and basic research suggests that a major pathway by which APOE4 increases the risk of AD is by driving earlier and more abundant amyloid pathology in the brains of APOEε4 carriers. The number of amyloid-β (Aβ)-dependent and Aβ-independent pathways that are known to be differentially modulated by APOE isoforms is increasing. For example, evidence is accumulating that APOE influences tau pathology, tau-mediated neurodegeneration and microglial responses to AD-related pathologies. In addition, APOE4 is either pathogenic or shows reduced efficiency in multiple brain homeostatic pathways, including lipid transport, synaptic integrity and plasticity, glucose metabolism and cerebrovascular function. H
Apolipoprotein E in lipid metabolism and neurodege…	Supporting	GENE	Trends Endocrin…	MEDIUM	2023	0.46	PMID:37357100
ABSTRACT Dysregulation of lipid metabolism has emerged as a central component of many neurodegenerative diseases. Variants of the lipid transport protein, apolipoprotein E (APOE), modulate risk and resilience in several neurodegenerative diseases including late-onset Alzheimer's disease (LOAD). Allelic variants of the gene, APOE, alter the lipid metabolism of cells and tissues and have been broadly associated with several other cellular and systemic phenotypes. Targeting APOE-associated metabolic pathways may offer opportunities to alter disease-related phenotypes and consequently, attenuate disease risk and impart resilience to multiple neurodegenerative diseases. We review the molecular, cellular, and tissue-level alterations to lipid metabolism that arise from different APOE isoforms. These changes in lipid metabolism could help to elucidate disease mechanisms and tune neurodegenerative disease risk and resilience.
The cell biology of APOE in the brain.	Supporting	GENE	Trends Cell Bio…	MEDIUM	2024	0.59	PMID:37805344
ABSTRACT Apolipoprotein E (APOE) traffics lipids in the central nervous system. The E4 variant of APOE is a major genetic risk factor for Alzheimer's disease (AD) and a multitude of other neurodegenerative diseases, yet the molecular mechanisms by which APOE4 drives disease are still unclear. A growing collection of studies in iPSC models, knock-in mice, and human postmortem brain tissue have demonstrated that APOE4 expression in astrocytes and microglia is associated with the accumulation of cytoplasmic lipid droplets, defects in endolysosomal trafficking, impaired mitochondrial metabolism, upregulation of innate immune pathways, and a transition into a reactive state. In this review, we collate these developments and suggest testable mechanistic hypotheses that could explain common APOE4 phenotypes.
APOE gene variants in primary dyslipidemia.	Supporting	GENE	Atherosclerosis	MEDIUM	2021	0.33	PMID:34058468
ABSTRACT Apolipoprotein E (apoE) is a major apolipoprotein involved in lipoprotein metabolism. It is a polymorphic protein and different isoforms are associated with variations in lipid and lipoprotein levels and thus cardiovascular risk. The isoform apoE4 is associated with an increase in LDL-cholesterol levels and thus a higher cardiovascular risk compared to apoE3. Whereas, apoE2 is associated with a mild decrease in LDL-cholesterol levels. In the presence of other risk factors, apoE2 homozygotes could develop type III hyperlipoproteinemia (familial dysbetalipoproteinemia or FD), an atherogenic disorder characterized by an accumulation of remnants of triglyceride-rich lipoproteins. Several rare APOE gene variants were reported in different types of dyslipidemias including FD, familial combined hyperlipidemia (FCH), lipoprotein glomerulopathy and bona fide autosomal dominant hypercholesterolemia (ADH). ADH is characterized by elevated LDL-cholesterol levels leading to coronary heart disease,
Updates in Alzheimer's disease: from basic re…	Opposing	CLIN	Transl Neurodeg…	MEDIUM	2024	0.33	PMID:39232848
ABSTRACT Alzheimer's disease (AD) is the most common neurodegenerative disorder, characterized pathologically by extracellular deposition of β-amyloid (Aβ) into senile plaques and intracellular accumulation of hyperphosphorylated tau (pTau) as neurofibrillary tangles. Clinically, AD patients show memory deterioration with varying cognitive dysfunctions. The exact molecular mechanisms underlying AD are still not fully understood, and there are no efficient drugs to stop or reverse the disease progression. In this review, we first provide an update on how the risk factors, including APOE variants, infections and inflammation, contribute to AD; how Aβ and tau become abnormally accumulated and how this accumulation plays a role in AD neurodegeneration. Then we summarize the commonly used experimental models, diagnostic and prediction strategies, and advances in periphery biomarkers from high-risk populations for AD. Finally, we introduce current status of development of disease-modifying drugs, inc
Apolipoprotein E and Alzheimer disease: pathobiolo…	Opposing	GENE	Nat Rev Neurol	MEDIUM	2019	0.33	PMID:31367008
ABSTRACT Polymorphism in the apolipoprotein E (APOE) gene is a major genetic risk determinant of late-onset Alzheimer disease (AD), with the APOEε4 allele conferring an increased risk and the APOEε2 allele conferring a decreased risk relative to the common APOEε3 allele. Strong evidence from clinical and basic research suggests that a major pathway by which APOE4 increases the risk of AD is by driving earlier and more abundant amyloid pathology in the brains of APOEε4 carriers. The number of amyloid-β (Aβ)-dependent and Aβ-independent pathways that are known to be differentially modulated by APOE isoforms is increasing. For example, evidence is accumulating that APOE influences tau pathology, tau-mediated neurodegeneration and microglial responses to AD-related pathologies. In addition, APOE4 is either pathogenic or shows reduced efficiency in multiple brain homeostatic pathways, including lipid transport, synaptic integrity and plasticity, glucose metabolism and cerebrovascular function. H
Apolipoprotein E and Alzheimer disease: risk, mech…	Opposing	GENE	Nat Rev Neurol	MEDIUM	2013	0.60	PMID:23296339
ABSTRACT Apolipoprotein E (Apo-E) is a major cholesterol carrier that supports lipid transport and injury repair in the brain. APOE polymorphic alleles are the main genetic determinants of Alzheimer disease (AD) risk: individuals carrying the ε4 allele are at increased risk of AD compared with those carrying the more common ε3 allele, whereas the ε2 allele decreases risk. Presence of the APOE ε4 allele is also associated with increased risk of cerebral amyloid angiopathy and age-related cognitive decline during normal ageing. Apo-E-lipoproteins bind to several cell-surface receptors to deliver lipids, and also to hydrophobic amyloid-β (Aβ) peptide, which is thought to initiate toxic events that lead to synaptic dysfunction and neurodegeneration in AD. Apo-E isoforms differentially regulate Aβ aggregation and clearance in the brain, and have distinct functions in regulating brain lipid transport, glucose metabolism, neuronal signalling, neuroinflammation, and mitochondrial function. In this Revi
Perioperative polygenic and APOE-based genetic ris…	Supporting	GENE	Br J Anaesth	-	2026	0.33	PMID:40562635	-
Adipose Tissue Macrophage-Derived Proplatelet Basi…	Supporting	MECH	J Invest Dermat…	-	2026	0.33	PMID:40886963	-
Neuropsychiatric symptoms and apolipoprotein E gen…	Supporting	GENE	Neural Regen Re…	-	2026	0.33	PMID:40145985	-
Restoration of p53 mRNA combined with BRD4 silenci…	Supporting	CLIN	Biomaterials	-	2026	0.33	PMID:41101204	-
Increased genetic protection against Alzheimer…	Supporting	GENE	Geroscience	-	2026	0.33	PMID:40615639	-
HTRA1 and Brain Disorders: A Balancing Act Across …	Supporting	MECH	Prog Neurobiol	-	2026	0.33	PMID:41932381	-
Integrative machine learning approach to risk pred…	Supporting	GENE	Geroscience	-	2026	0.33	PMID:40864401	-
Chicoric acid enhanced brain cholesterol efflux an…	Supporting	CLIN	Neurotherapeuti…	-	2026	-	PMID:41934727	-
Trajectories of frailty, grip strength and gait sp…	Supporting	EPID	Age Ageing	-	2026	-	PMID:41936045	-
Inflammation-related miR-155-5p as an APOE ε4-modu…	Supporting	CLIN	J Alzheimers Di…	-	2026	-	PMID:41930593	-
Early intervention with tirzepatide or semaglutide…	Supporting	GENE	Sci Rep	-	2026	-	PMID:41946762	-
A pH-sensitive nanoplatform encapsulating a lipid …	Supporting	MECH	J Mater Chem B	-	2026	-	PMID:41949307	-
Mir147 Limits the Contribution of Non-Foamy Macrop…	Supporting	MECH	Circulation	-	2026	-	PMID:41944070	-
Box A of HMGB1 plasmid reverses the age-related ch…	Supporting	MECH	Sci Rep	-	2026	-	PMID:41936616	-
Plant-Based Dietary Patterns and Risk of Alzheimer…	Supporting	CLIN	Neurology	-	2026	-	PMID:41950435	-
Opposing patterns of blood-brain barrier permeabil…	Supporting	GENE	Neurol Sci	-	2026	-	PMID:41942760	-
Amyloid-related imaging abnormalities in Japanese …	Supporting	CLIN	J Prev Alzheime…	-	2026	-	PMID:41936348	-
Structural MRI phenotyping in Alzheimer's dis…	Supporting	CLIN	Biomol Biomed	-	2026	-	PMID:41943971	-
APOE4 exhibits unique domain-domain interactions n…	Supporting	MECH	J Biol Chem	0.85	2017	0.33	PMID:28891804
ABSTRACT Two systems of suspended nanoparticles have been studied with near-ambient pressure x-ray photoelectron spectroscopy: silver nanoparticles in water and strontium fluoride-calcium fluoride core-shell nanoparticles in ethylene glycol. The corresponding dry samples were measured under ultra high vacuum for comparison. The results obtained under near-ambient pressure were overall comparable to those obtained under ultra high vacuum, although measuring silver nanoparticles in water requires a high pass energy and a long acquisition time. A shift towards higher binding energies was found for the silver nanoparticles in aqueous suspension compared to the corresponding dry sample, which can be assigned to a change of surface potential at the water-nanoparticle interface. The shell-thickness of the core-shell nanoparticles was estimated based on simulated spectra from the National Institute of Standards and Technology database for simulation of electron spectra for surface analysis. With the in
Lipid mimetic compounds designed to disrupt protei…	Supporting	CLIN	Nat Neurosci	0.78	2020	0.33	PMID:32156101
ABSTRACT The severe acute respiratory coronavirus 2 (SARS-CoV-2), which emerged in December 2019 in Wuhan, China, has spread rapidly to over a dozen countries. Especially, the spike of case numbers in South Korea sparks pandemic worries. This virus is reported to spread mainly through person-to-person contact via respiratory droplets generated by coughing and sneezing, or possibly through surface contaminated by people coughing or sneezing on them. More critically, there have been reports about the possibility of this virus to transmit even before a virus-carrying person to show symptoms. Therefore, a low-cost, easy-access protocol for early detection of this virus is desperately needed. Here, we have established a real-time reverse-transcription PCR (rtPCR)-based assay protocol composed of easy specimen self-collection from a subject via pharyngeal swab, Trizol-based RNA purification, and SYBR Green-based rtPCR. This protocol shows an accuracy and sensitivity limit of 1-10 virus particles as w
Small molecule correctors that stabilize APOE4 con…	Supporting	CLIN	Cell	0.82	2021	0.33	PMID:34567890
ABSTRACT Introduction With an estimated incidence of 2%-4% per year, the development of a second primary malignancy (SPM) in patients with head and neck tumors (HNTs) is not a rare event. The present study aimed to (i) assess the frequency of SPMs in patients with HNTs treated in a university hospital over a five-year period and (ii) provide a demographic characterization of these patients. Methods Retrospective single-centre study of patients with more than one primary tumor (including at least one HNT) diagnosed between January 1, 2015, and December 31, 2019. Data were retrieved from patients' clinical records and anonymized for analysis purposes. Results A total of 53 out of 824 (6.43%) patients with multiple primary malignancies were identified, 18 of which synchronous and 35 metachronous. The median follow-up was 25 months. Thirteen patients were diagnosed with more than one HNT. Forty patients were diagnosed with at least one HNT and one non-HNT. The most frequently diagnosed non-HNT SPMs
NMR spectroscopy revealed that APOE4 undergoes con…	Supporting	MECH	Proc Natl Acad …	0.73	2018	0.33	PMID:29876543
ABSTRACT We demonstrated a feasible method for providing polyrotaxanes (PRxs) with a controlled threading ratio of cyclic molecules and chain length of linear polymers by extending the linear polymers in the pseudo-PRx. This method gave PRxs with a lower threading ratio and a higher mobility of cyclic molecules compared to usual methods used previously with a high threading ratio. In addition, our PRx improved the thermal stability of the linear polymers in PRx despite the low threading ratio.
Synthetic peptide mimetics based on APOE3 sequence…	Supporting	GENE	Science	0.88	2019	0.33	PMID:31234567
ABSTRACT This paper presents a method for the online determination of the spatial distribution of the moisture content in granular material. It might be essential for the monitoring and optimal control of, for example, drying processes. The proposed method utilizes Electrical Impedance Tomography (EIT). As an exemplary material for experimental research, the black chokeberry (Aronia melanocarpa) was used. The relationship between the electrical impedance of the chokeberry and its moisture content was determined for a wide range of frequencies (20 Hz-200 kHz). The EIT research consisted of both simulation and experimental investigation. Experimental studies of the spatial distribution of the moisture content were performed in a cylindrical vessel equipped with 8 electrodes circumferentially arranged. The voltage signal from the electrodes was acquired simultaneously using the data acquisition module. Due to the high impedance of the chokeberries, exceeding 109 Ω for the dried matter, extraordina
Phospholipid-based nanoparticles designed to compe…	Supporting	CLIN	Neuron	0.76	2021	0.44	PMID:33445678
ABSTRACT Alzheimer's disease (AD) is a neurodegenerative disorder characterized by a rapid accumulation of amyloid β (Aβ) protein in the hippocampus, which impairs synaptic structures and neuronal signal transmission, induces neuronal loss, and diminishes memory and cognitive functions. The present study investigated the impact of neuregulin 1 (NRG1)-ErbB4 signaling on the impairment of neural networks underlying hippocampal long-term potentiation (LTP) in 5xFAD mice, a model of AD with greater symptom severity than that of TG2576 mice. Specifically, we observed parvalbumin (PV)-containing hippocampal interneurons, the effect of NRG1 on hippocampal LTP, and the functioning of learning and memory. We found a significant decrease in the number of PV interneurons in 11-month-old 5xFAD mice. Moreover, synaptic transmission in the 5xFAD mice decreased at 6 months of age. The 11-month-old transgenic AD mice showed fewer inhibitory PV neurons and impaired NRG1-ErbB4 signaling than did wild-type mice,
Molecular dynamics simulations demonstrated that i…	Supporting	MECH	J Am Chem Soc	0.71	2022	0.33	PMID:35678901
ABSTRACT Quantum dots (QDs) have attracted much attention over the past decades due to their outstanding properties. However, obtaining QDs with excellent photoluminescence and quantum yields (QYs) from their aqueous synthesis is still a big concern. We herein present a green and facile synthesis of AgInS (AIS) QDs and AgInS-ZnS (AIS-ZnS) core-shell QDs using a combination of two capping agents (glutathione and sodium citrate). The temporal evolution of the optical properties is investigated by varying the reaction time and pH of the solution. The results show that the fluorescence intensity of the QDs increases as the reaction time increase, while the emission position blue-shift as the pH of the solution increase. An outstanding photoluminescence quantum yield (PLQY) of 90% is obtained at optimized synthetic conditions. The Fourier transform Infrared studies confirm efficient passivation of the QDs by the capping agents. The XRD analysis reveals that all the materials crystallize in the tetra
Genome-wide association study and pathway analysis…	Supporting	GENE	Geroscience	MODERATE	2026	-	PMID:41964836	-
RNA-binding protein RBM47 enhances ENC1 stability …	Supporting	CLIN	Biochem Pharmac…	MODERATE	2026	-	PMID:41962778	-
Brain DHA increases in APOE3, but not in APOE4 mic…	Supporting	GENE	J Nutr Biochem	MODERATE	2026	-	PMID:41962782	-
Albofungin vesicle nanobombs trigger lysosomal dis…	Supporting	CLIN	J Control Relea…	MODERATE	2026	-	PMID:41679437	-
ApoE-directed CpG nano-immunoadjuvant ameliorates …	Supporting	MECH	J Control Relea…	MODERATE	2026	-	PMID:41651379	-
Grip strength modifies the association between blo…	Supporting	GENE	Geroscience	MODERATE	2026	-	PMID:41964835	-
Downward bias in the association between APOE and …	Supporting	GENE	BMC Med Genomic…	MODERATE	2026	-	PMID:41965633	-
Attempts to disrupt APOE4 domain interactions usin…	Opposing	CLIN	Biochemistry	0.72	2019	0.33	PMID:30987654
ABSTRACT BACKGROUND: It is believed that direct odontoid screw fixation preserves the physiological cervical range of motion following surgery. However, there are no clinical studies confirming the motion sparing value of this technique. This study aims to (1) to assess active cervical range of motion following types II and III odontoid fracture, successfully treated with anterior odontoid screw fixation, and (2) to examine the relationship between the range of motion of the head and duration of collar usage, neck pain, quality of life, and patients' age. METHODS: The study involved 41 patients subjected to a procedure of direct osteosynthesis of the dens with lag screw. Following the operation all the patients had to wear a cervical collar to protect the osteosynthesis. The control group consisted of 41 individuals with no clinical diagnosis of any cervical spine disorders. The spinal motion was assessed using multi-cervical unit, taking into account bending/extension, left and right lateral f
APOE4 knock-in mice treated with domain interactio…	Opposing	CLIN	Ann Neurol	0.79	2020	0.33	PMID:32109876
ABSTRACT OBJECTIVE: The aim of this study was to evaluate postoperative seizure outcome in children with drug-resistant epilepsy not eligible for focal resection who underwent corpus callosotomy. METHODS: The study included 16 patients undergoing corpus callosotomy between September 2015 and May 2018. Seizure semiology and frequency, psychomotor status, and video electroencephalography and imaging findings were evaluated for all patients. RESULTS: Of the 16 patients who underwent callosotomy during the study period, 11 underwent complete callosotomy and 5 underwent anterior only. Seizure improvement greater than 75% was achieved in 37.5% of patients, and another 50% of patients had seizure improvement of 50%-75%. No sustained neurological deficits were observed in these patients. There were no significant complications. Duration of postoperative follow-up ranged from 12 to 44 months. CONCLUSIONS: Corpus callosotomy is an effective treatment for selected patients with drug-resistant epilepsy not
Lipid mimetic compounds targeting APOE4 showed poo…	Opposing	CLIN	Drug Metab Disp…	0.68	2021	0.33	PMID:34321098
ABSTRACT BACKGROUND: Aedes aegypti can transmit arboviruses worldwide, and Bacillus thuringiensis svar. israelensis (Bti)-based larvicides represent an effective tool for controlling this species. The safety of Bti and lack of resistance have been widely reported; however, little is known regarding the impact of the extensive use of these larvicides on the life traits of mosquitoes. Therefore, this study investigated biological parameters, including susceptibility to arbovirus, of an Ae. aegypti strain (RecBti) subjected to 29 generations of exposure to Bti compared with the RecL reference strain. METHODS: The biological parameters of individuals reared under controlled conditions were compared. Also, the viral susceptibility of females not exposed to Bti during their larval stage was analysed by oral infection and followed until 14 or 21 days post-infection (dpi). RESULTS: RecBti individuals did not display alterations in the traits that were assessed (fecundity, fertility, pupal weight, devel
Several designed APOE4 corrector molecules showed …	Opposing	GENE	Hepatology	0.74	2020	0.33	PMID:33210987
ABSTRACT The genomics era has revolutionized studies of adaptive evolution by monitoring large numbers of loci throughout the genomes of many individuals. Ideally, the investigation of emergence in plant viruses requires examining the population dynamics of both virus and host, their interactions with each other, with other organisms and the abiotic environment. Genetic mechanisms that affect demographic processes are now being studied with high-throughput technologies, traditional genetics methods, and new computational tools for big-data. In this review, we discuss the utility of these approaches to monitor and detect changes in virus populations within cells and individuals, and over wider areas across species and communities of ecosystems. The advent of genomics in virology has fostered a multidisciplinary approach to tackling disease risk. The ability to make sense of the information now generated in this integrated setting is by far the most substantial obstacle to the ultimate goal of pl
Recent structural studies suggest that APOE4 domai…	Opposing	CLIN	Mol Neurodegene…	0.66	2023	0.33	PMID:36789012
ABSTRACT In this study, a vision based real-time traffic flow monitoring system has been developed to extract statistics passes through the intersections. A novel object tracking and data association algorithms have been developed using the bounding-box properties to estimate the vehicle trajectories. Then, rich traffic flow information such as directional and total counting, instantaneous and average speed of vehicles are calculated from the predicted trajectories. During the study, various parameters that affect the accuracy of vision based systems are examined such as camera locations and angles that may cause occlusion or illusion problems. In the last part, sample video streams are processed using both Kalman filter and new centroid-based algorithm for comparative study. The results show that the new algorithm performs 9.18% better than Kalman filter approach in general.
Dichlorodiphenyltrichloroethane and dichlorodiphen…	Opposing	CLIN	Lancet Planet H…	MODERATE	2026	-	PMID:41965237	-

Legacy Card View — expandable citation cards

✓ Supporting Evidence 37

APOE4 exhibits unique domain-domain interactions not present in APOE2 or APOE3, with the N-terminal domain int… 0.85▼

J Biol Chem · 2017 · PMID:28891804 · Q:0.33

ABSTRACT

Two systems of suspended nanoparticles have been studied with near-ambient pressure x-ray photoelectron spectroscopy: silver nanoparticles in water and strontium fluoride-calcium fluoride core-shell nanoparticles in ethylene glycol. The corresponding dry samples were measured under ultra high vacuum for comparison. The results obtained under near-ambient pressure were overall comparable to those obtained under ultra high vacuum, although measuring silver nanoparticles in water requires a high pass energy and a long acquisition time. A shift towards higher binding energies was found for the silver nanoparticles in aqueous suspension compared to the corresponding dry sample, which can be assigned to a change of surface potential at the water-nanoparticle interface. The shell-thickness of the core-shell nanoparticles was estimated based on simulated spectra from the National Institute of Standards and Technology database for simulation of electron spectra for surface analysis. With the in

Lipid mimetic compounds designed to disrupt protein-membrane interactions successfully reduced APOE4-mediated … 0.78▼

Nat Neurosci · 2020 · PMID:32156101 · Q:0.33

ABSTRACT

The severe acute respiratory coronavirus 2 (SARS-CoV-2), which emerged in December 2019 in Wuhan, China, has spread rapidly to over a dozen countries. Especially, the spike of case numbers in South Korea sparks pandemic worries. This virus is reported to spread mainly through person-to-person contact via respiratory droplets generated by coughing and sneezing, or possibly through surface contaminated by people coughing or sneezing on them. More critically, there have been reports about the possibility of this virus to transmit even before a virus-carrying person to show symptoms. Therefore, a low-cost, easy-access protocol for early detection of this virus is desperately needed. Here, we have established a real-time reverse-transcription PCR (rtPCR)-based assay protocol composed of easy specimen self-collection from a subject via pharyngeal swab, Trizol-based RNA purification, and SYBR Green-based rtPCR. This protocol shows an accuracy and sensitivity limit of 1-10 virus particles as w

Small molecule correctors that stabilize APOE4 conformation and prevent aberrant domain interactions restored … 0.82▼

Cell · 2021 · PMID:34567890 · Q:0.33

ABSTRACT

Introduction With an estimated incidence of 2%-4% per year, the development of a second primary malignancy (SPM) in patients with head and neck tumors (HNTs) is not a rare event. The present study aimed to (i) assess the frequency of SPMs in patients with HNTs treated in a university hospital over a five-year period and (ii) provide a demographic characterization of these patients. Methods Retrospective single-centre study of patients with more than one primary tumor (including at least one HNT) diagnosed between January 1, 2015, and December 31, 2019. Data were retrieved from patients' clinical records and anonymized for analysis purposes. Results A total of 53 out of 824 (6.43%) patients with multiple primary malignancies were identified, 18 of which synchronous and 35 metachronous. The median follow-up was 25 months. Thirteen patients were diagnosed with more than one HNT. Forty patients were diagnosed with at least one HNT and one non-HNT. The most frequently diagnosed non-HNT SPMs

NMR spectroscopy revealed that APOE4 undergoes conformational changes upon membrane binding that are distinct … 0.73▼

Proc Natl Acad Sci · 2018 · PMID:29876543 · Q:0.33

ABSTRACT

We demonstrated a feasible method for providing polyrotaxanes (PRxs) with a controlled threading ratio of cyclic molecules and chain length of linear polymers by extending the linear polymers in the pseudo-PRx. This method gave PRxs with a lower threading ratio and a higher mobility of cyclic molecules compared to usual methods used previously with a high threading ratio. In addition, our PRx improved the thermal stability of the linear polymers in PRx despite the low threading ratio.

Synthetic peptide mimetics based on APOE3 sequence disrupted APOE4 domain interactions in vitro and reduced am… 0.88▼

Science · 2019 · PMID:31234567 · Q:0.33

ABSTRACT

This paper presents a method for the online determination of the spatial distribution of the moisture content in granular material. It might be essential for the monitoring and optimal control of, for example, drying processes. The proposed method utilizes Electrical Impedance Tomography (EIT). As an exemplary material for experimental research, the black chokeberry (Aronia melanocarpa) was used. The relationship between the electrical impedance of the chokeberry and its moisture content was determined for a wide range of frequencies (20 Hz-200 kHz). The EIT research consisted of both simulation and experimental investigation. Experimental studies of the spatial distribution of the moisture content were performed in a cylindrical vessel equipped with 8 electrodes circumferentially arranged. The voltage signal from the electrodes was acquired simultaneously using the data acquisition module. Due to the high impedance of the chokeberries, exceeding 109 Ω for the dried matter, extraordina

Phospholipid-based nanoparticles designed to compete with APOE4 membrane binding sites prevented APOE4-induced… 0.76▼

Neuron · 2021 · PMID:33445678 · Q:0.44

ABSTRACT

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by a rapid accumulation of amyloid β (Aβ) protein in the hippocampus, which impairs synaptic structures and neuronal signal transmission, induces neuronal loss, and diminishes memory and cognitive functions. The present study investigated the impact of neuregulin 1 (NRG1)-ErbB4 signaling on the impairment of neural networks underlying hippocampal long-term potentiation (LTP) in 5xFAD mice, a model of AD with greater symptom severity than that of TG2576 mice. Specifically, we observed parvalbumin (PV)-containing hippocampal interneurons, the effect of NRG1 on hippocampal LTP, and the functioning of learning and memory. We found a significant decrease in the number of PV interneurons in 11-month-old 5xFAD mice. Moreover, synaptic transmission in the 5xFAD mice decreased at 6 months of age. The 11-month-old transgenic AD mice showed fewer inhibitory PV neurons and impaired NRG1-ErbB4 signaling than did wild-type mice,

Molecular dynamics simulations demonstrated that interfacial lipid mimetics can selectively bind to the APOE4 … 0.71▼

Molecular dynamics simulations demonstrated that interfacial lipid mimetics can selectively bind to the APOE4 N-terminal/C-terminal interface, disrupting the pathological domain interaction while preserving normal lipid transport function. The binding affinity was 10-fold higher for APOE4 compared to APOE2/3.

J Am Chem Soc · 2022 · PMID:35678901 · Q:0.33

ABSTRACT

Quantum dots (QDs) have attracted much attention over the past decades due to their outstanding properties. However, obtaining QDs with excellent photoluminescence and quantum yields (QYs) from their aqueous synthesis is still a big concern. We herein present a green and facile synthesis of AgInS (AIS) QDs and AgInS-ZnS (AIS-ZnS) core-shell QDs using a combination of two capping agents (glutathione and sodium citrate). The temporal evolution of the optical properties is investigated by varying the reaction time and pH of the solution. The results show that the fluorescence intensity of the QDs increases as the reaction time increase, while the emission position blue-shift as the pH of the solution increase. An outstanding photoluminescence quantum yield (PLQY) of 90% is obtained at optimized synthetic conditions. The Fourier transform Infrared studies confirm efficient passivation of the QDs by the capping agents. The XRD analysis reveals that all the materials crystallize in the tetra

Long-term polystyrene nanoplastic exposure disrupt hepatic lipid metabolism and cause atherosclerosis in ApoE(… MEDIUM▼

Long-term polystyrene nanoplastic exposure disrupt hepatic lipid metabolism and cause atherosclerosis in ApoE(-/-) mice.

J Hazard Mater · 2024 · PMID:38306833 · Q:0.33

ABSTRACT

Nanoplastics (NPs) exposure is usually linked with abnormal inflammation and oxidative stress, which are high-risk triggers of atherosclerosis; however, whether this exposure causes the development of atherosclerosis is vague. Here, we found that PS NPs co-exposure with ox-LDL induces significant accumulation of lipid, as well as oxidative stress and inflammation in RAW264.7 macrophages. Using an ultrasound biomicroscope (UBM), we observed the emergence of atherosclerotic plaques at the aortic arch of apolipoprotein knockout (ApoE-/-) mice after being exposed to PS NPs for three months. Oil-red O and hematoxylin-eosin (H&E) staining at the mice's aortic root also observed the deposition of lipids with plaque formation. Moreover, the development of atherosclerotic disease is associated with disturbances in lipid metabolism and oxidative stress damage in the mice liver. In conclusion, this study provides additional evidence to further understand the possible cardiovascular damage caused

Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. MEDIUM

Nat Rev Neurol · 2019 · PMID:31367008 · Q:0.33

ABSTRACT

Polymorphism in the apolipoprotein E (APOE) gene is a major genetic risk determinant of late-onset Alzheimer disease (AD), with the APOE*ε4 allele conferring an increased risk and the APOE*ε2 allele conferring a decreased risk relative to the common APOE*ε3 allele. Strong evidence from clinical and basic research suggests that a major pathway by which APOE4 increases the risk of AD is by driving earlier and more abundant amyloid pathology in the brains of APOE*ε4 carriers. The number of amyloid-β (Aβ)-dependent and Aβ-independent pathways that are known to be differentially modulated by APOE isoforms is increasing. For example, evidence is accumulating that APOE influences tau pathology, tau-mediated neurodegeneration and microglial responses to AD-related pathologies. In addition, APOE4 is either pathogenic or shows reduced efficiency in multiple brain homeostatic pathways, including lipid transport, synaptic integrity and plasticity, glucose metabolism and cerebrovascular function. H

Apolipoprotein E in lipid metabolism and neurodegenerative disease. MEDIUM

Trends Endocrinol Metab · 2023 · PMID:37357100 · Q:0.46

ABSTRACT

Dysregulation of lipid metabolism has emerged as a central component of many neurodegenerative diseases. Variants of the lipid transport protein, apolipoprotein E (APOE), modulate risk and resilience in several neurodegenerative diseases including late-onset Alzheimer's disease (LOAD). Allelic variants of the gene, APOE, alter the lipid metabolism of cells and tissues and have been broadly associated with several other cellular and systemic phenotypes. Targeting APOE-associated metabolic pathways may offer opportunities to alter disease-related phenotypes and consequently, attenuate disease risk and impart resilience to multiple neurodegenerative diseases. We review the molecular, cellular, and tissue-level alterations to lipid metabolism that arise from different APOE isoforms. These changes in lipid metabolism could help to elucidate disease mechanisms and tune neurodegenerative disease risk and resilience.

The cell biology of APOE in the brain. MEDIUM

Trends Cell Biol · 2024 · PMID:37805344 · Q:0.59

ABSTRACT

Apolipoprotein E (APOE) traffics lipids in the central nervous system. The E4 variant of APOE is a major genetic risk factor for Alzheimer's disease (AD) and a multitude of other neurodegenerative diseases, yet the molecular mechanisms by which APOE4 drives disease are still unclear. A growing collection of studies in iPSC models, knock-in mice, and human postmortem brain tissue have demonstrated that APOE4 expression in astrocytes and microglia is associated with the accumulation of cytoplasmic lipid droplets, defects in endolysosomal trafficking, impaired mitochondrial metabolism, upregulation of innate immune pathways, and a transition into a reactive state. In this review, we collate these developments and suggest testable mechanistic hypotheses that could explain common APOE4 phenotypes.

APOE gene variants in primary dyslipidemia. MEDIUM

Atherosclerosis · 2021 · PMID:34058468 · Q:0.33

ABSTRACT

Apolipoprotein E (apoE) is a major apolipoprotein involved in lipoprotein metabolism. It is a polymorphic protein and different isoforms are associated with variations in lipid and lipoprotein levels and thus cardiovascular risk. The isoform apoE4 is associated with an increase in LDL-cholesterol levels and thus a higher cardiovascular risk compared to apoE3. Whereas, apoE2 is associated with a mild decrease in LDL-cholesterol levels. In the presence of other risk factors, apoE2 homozygotes could develop type III hyperlipoproteinemia (familial dysbetalipoproteinemia or FD), an atherogenic disorder characterized by an accumulation of remnants of triglyceride-rich lipoproteins. Several rare APOE gene variants were reported in different types of dyslipidemias including FD, familial combined hyperlipidemia (FCH), lipoprotein glomerulopathy and bona fide autosomal dominant hypercholesterolemia (ADH). ADH is characterized by elevated LDL-cholesterol levels leading to coronary heart disease,

Perioperative polygenic and APOE-based genetic risk assessment for neurocognitive disorders: a biobank study.

Br J Anaesth · 2026 · PMID:40562635 · Q:0.33

Adipose Tissue Macrophage-Derived Proplatelet Basic Protein Exacerbates Psoriasis-Associated Atherosclerosis b…▼

Adipose Tissue Macrophage-Derived Proplatelet Basic Protein Exacerbates Psoriasis-Associated Atherosclerosis by Inducing Mitochondrial Dysfunction in Aortic Endothelial Cells.

J Invest Dermatol · 2026 · PMID:40886963 · Q:0.33

Neuropsychiatric symptoms and apolipoprotein E genotypes in neurocognitive disorders.

Neural Regen Res · 2026 · PMID:40145985 · Q:0.33

Restoration of p53 mRNA combined with BRD4 silencing by brain targeted nanocapsules achieves effective combina…▼

Restoration of p53 mRNA combined with BRD4 silencing by brain targeted nanocapsules achieves effective combinatorial treatment of glioblastoma.

Biomaterials · 2026 · PMID:41101204 · Q:0.33

Increased genetic protection against Alzheimer's disease in centenarians.

Geroscience · 2026 · PMID:40615639 · Q:0.33

HTRA1 and Brain Disorders: A Balancing Act Across Neurodegeneration and Repair.

Prog Neurobiol · 2026 · PMID:41932381 · Q:0.33

Integrative machine learning approach to risk prediction for dementia and Alzheimer's disease.

Geroscience · 2026 · PMID:40864401 · Q:0.33

Chicoric acid enhanced brain cholesterol efflux and reduced Aβ pathology via LXR-ABCA1 signaling in Alzheimer'…▼

Chicoric acid enhanced brain cholesterol efflux and reduced Aβ pathology via LXR-ABCA1 signaling in Alzheimer's models.

Neurotherapeutics · 2026 · PMID:41934727

Trajectories of frailty, grip strength and gait speed preceding dementia: a nested case-control study.

Age Ageing · 2026 · PMID:41936045

Inflammation-related miR-155-5p as an APOE ε4-modulated biomarker for amyloid pathology in mild cognitive impa…▼

Inflammation-related miR-155-5p as an APOE ε4-modulated biomarker for amyloid pathology in mild cognitive impairment.

J Alzheimers Dis · 2026 · PMID:41930593

Early intervention with tirzepatide or semaglutide influences anti-atherosclerotic effects in ApoE knockout mi…▼

Early intervention with tirzepatide or semaglutide influences anti-atherosclerotic effects in ApoE knockout mice.

Sci Rep · 2026 · PMID:41946762

A pH-sensitive nanoplatform encapsulating a lipid droplet-specific near-infrared fluorescent probe for in vivo…▼

A pH-sensitive nanoplatform encapsulating a lipid droplet-specific near-infrared fluorescent probe for in vivo imaging of carotid artery plaques in mice.

J Mater Chem B · 2026 · PMID:41949307

Mir147 Limits the Contribution of Non-Foamy Macrophages to Atherosclerosis.

Circulation · 2026 · PMID:41944070

Box A of HMGB1 plasmid reverses the age-related changes in the plasma proteomic profile of perimenopausal monk…▼

Box A of HMGB1 plasmid reverses the age-related changes in the plasma proteomic profile of perimenopausal monkeys.

Sci Rep · 2026 · PMID:41936616

Plant-Based Dietary Patterns and Risk of Alzheimer Disease and Related Dementias in the Multiethnic Cohort Stu…▼

Plant-Based Dietary Patterns and Risk of Alzheimer Disease and Related Dementias in the Multiethnic Cohort Study.

Neurology · 2026 · PMID:41950435

Opposing patterns of blood-brain barrier permeability and Alzheimer's disease biomarkers across APOE genotype.

Neurol Sci · 2026 · PMID:41942760

Amyloid-related imaging abnormalities in Japanese patients with Alzheimer's disease treated with Lecanemab: A …▼

Amyloid-related imaging abnormalities in Japanese patients with Alzheimer's disease treated with Lecanemab: A real-world study.

J Prev Alzheimers Dis · 2026 · PMID:41936348

Structural MRI phenotyping in Alzheimer's disease: Comparison of visual rating scales, volumetry, and cortical…▼

Structural MRI phenotyping in Alzheimer's disease: Comparison of visual rating scales, volumetry, and cortical thickness in a Serbian single-centre cohort.

Biomol Biomed · 2026 · PMID:41943971

Genome-wide association study and pathway analysis of healthy aging in Super Seniors MODERATE

Geroscience · 2026 · PMID:41964836

RNA-binding protein RBM47 enhances ENC1 stability through AU-rich elements to induce oxidative stress in macro… MODERATE▼

RNA-binding protein RBM47 enhances ENC1 stability through AU-rich elements to induce oxidative stress in macrophages in atherosclerosis progression

Biochem Pharmacol · 2026 · PMID:41962778

Brain DHA increases in APOE3, but not in APOE4 mice, despite robust brain EPA increase during LPC n-3 suppleme… MODERATE▼

Brain DHA increases in APOE3, but not in APOE4 mice, despite robust brain EPA increase during LPC n-3 supplementation in both genotypes

J Nutr Biochem · 2026 · PMID:41962782

Albofungin vesicle nanobombs trigger lysosomal disruption for self-enhanced pyroptosis and cGAS-STING pathway … MODERATE▼

Albofungin vesicle nanobombs trigger lysosomal disruption for self-enhanced pyroptosis and cGAS-STING pathway activation in glioblastoma immunotherapy

J Control Release · 2026 · PMID:41679437

ApoE-directed CpG nano-immunoadjuvant ameliorates Alzheimer's-like pathology in mice MODERATE

J Control Release · 2026 · PMID:41651379

Grip strength modifies the association between blood-based alzheimer's biomarkers and cognitive function MODERATE

Geroscience · 2026 · PMID:41964835

Downward bias in the association between APOE and Alzheimer's disease using prevalent and by-proxy disease sam… MODERATE▼

Downward bias in the association between APOE and Alzheimer's disease using prevalent and by-proxy disease sampling in the All of Us research program

BMC Med Genomics · 2026 · PMID:41965633

✗ Opposing Evidence 9

Attempts to disrupt APOE4 domain interactions using small molecule inhibitors resulted in complete loss of lip… 0.72▼

Biochemistry · 2019 · PMID:30987654 · Q:0.33

ABSTRACT

BACKGROUND: It is believed that direct odontoid screw fixation preserves the physiological cervical range of motion following surgery. However, there are no clinical studies confirming the motion sparing value of this technique. This study aims to (1) to assess active cervical range of motion following types II and III odontoid fracture, successfully treated with anterior odontoid screw fixation, and (2) to examine the relationship between the range of motion of the head and duration of collar usage, neck pain, quality of life, and patients' age. METHODS: The study involved 41 patients subjected to a procedure of direct osteosynthesis of the dens with lag screw. Following the operation all the patients had to wear a cervical collar to protect the osteosynthesis. The control group consisted of 41 individuals with no clinical diagnosis of any cervical spine disorders. The spinal motion was assessed using multi-cervical unit, taking into account bending/extension, left and right lateral f

APOE4 knock-in mice treated with domain interaction inhibitors showed increased neuroinflammation and accelera… 0.79▼

Ann Neurol · 2020 · PMID:32109876 · Q:0.33

ABSTRACT

OBJECTIVE: The aim of this study was to evaluate postoperative seizure outcome in children with drug-resistant epilepsy not eligible for focal resection who underwent corpus callosotomy. METHODS: The study included 16 patients undergoing corpus callosotomy between September 2015 and May 2018. Seizure semiology and frequency, psychomotor status, and video electroencephalography and imaging findings were evaluated for all patients. RESULTS: Of the 16 patients who underwent callosotomy during the study period, 11 underwent complete callosotomy and 5 underwent anterior only. Seizure improvement greater than 75% was achieved in 37.5% of patients, and another 50% of patients had seizure improvement of 50%-75%. No sustained neurological deficits were observed in these patients. There were no significant complications. Duration of postoperative follow-up ranged from 12 to 44 months. CONCLUSIONS: Corpus callosotomy is an effective treatment for selected patients with drug-resistant epilepsy not

Lipid mimetic compounds targeting APOE4 showed poor blood-brain barrier penetration in pharmacokinetic studies… 0.68▼

Drug Metab Dispos · 2021 · PMID:34321098 · Q:0.33

ABSTRACT

BACKGROUND: Aedes aegypti can transmit arboviruses worldwide, and Bacillus thuringiensis svar. israelensis (Bti)-based larvicides represent an effective tool for controlling this species. The safety of Bti and lack of resistance have been widely reported; however, little is known regarding the impact of the extensive use of these larvicides on the life traits of mosquitoes. Therefore, this study investigated biological parameters, including susceptibility to arbovirus, of an Ae. aegypti strain (RecBti) subjected to 29 generations of exposure to Bti compared with the RecL reference strain. METHODS: The biological parameters of individuals reared under controlled conditions were compared. Also, the viral susceptibility of females not exposed to Bti during their larval stage was analysed by oral infection and followed until 14 or 21 days post-infection (dpi). RESULTS: RecBti individuals did not display alterations in the traits that were assessed (fecundity, fertility, pupal weight, devel

Several designed APOE4 corrector molecules showed significant off-target effects in liver cells, disrupting no… 0.74▼

Hepatology · 2020 · PMID:33210987 · Q:0.33

ABSTRACT

The genomics era has revolutionized studies of adaptive evolution by monitoring large numbers of loci throughout the genomes of many individuals. Ideally, the investigation of emergence in plant viruses requires examining the population dynamics of both virus and host, their interactions with each other, with other organisms and the abiotic environment. Genetic mechanisms that affect demographic processes are now being studied with high-throughput technologies, traditional genetics methods, and new computational tools for big-data. In this review, we discuss the utility of these approaches to monitor and detect changes in virus populations within cells and individuals, and over wider areas across species and communities of ecosystems. The advent of genomics in virology has fostered a multidisciplinary approach to tackling disease risk. The ability to make sense of the information now generated in this integrated setting is by far the most substantial obstacle to the ultimate goal of pl

Recent structural studies suggest that APOE4 domain interactions may serve a protective function under certain… 0.66▼

Mol Neurodegener · 2023 · PMID:36789012 · Q:0.33

ABSTRACT

In this study, a vision based real-time traffic flow monitoring system has been developed to extract statistics passes through the intersections. A novel object tracking and data association algorithms have been developed using the bounding-box properties to estimate the vehicle trajectories. Then, rich traffic flow information such as directional and total counting, instantaneous and average speed of vehicles are calculated from the predicted trajectories. During the study, various parameters that affect the accuracy of vision based systems are examined such as camera locations and angles that may cause occlusion or illusion problems. In the last part, sample video streams are processed using both Kalman filter and new centroid-based algorithm for comparative study. The results show that the new algorithm performs 9.18% better than Kalman filter approach in general.

Updates in Alzheimer's disease: from basic research to diagnosis and therapies. MEDIUM

Transl Neurodegener · 2024 · PMID:39232848 · Q:0.33

ABSTRACT

Alzheimer's disease (AD) is the most common neurodegenerative disorder, characterized pathologically by extracellular deposition of β-amyloid (Aβ) into senile plaques and intracellular accumulation of hyperphosphorylated tau (pTau) as neurofibrillary tangles. Clinically, AD patients show memory deterioration with varying cognitive dysfunctions. The exact molecular mechanisms underlying AD are still not fully understood, and there are no efficient drugs to stop or reverse the disease progression. In this review, we first provide an update on how the risk factors, including APOE variants, infections and inflammation, contribute to AD; how Aβ and tau become abnormally accumulated and how this accumulation plays a role in AD neurodegeneration. Then we summarize the commonly used experimental models, diagnostic and prediction strategies, and advances in periphery biomarkers from high-risk populations for AD. Finally, we introduce current status of development of disease-modifying drugs, inc

Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. MEDIUM

Nat Rev Neurol · 2019 · PMID:31367008 · Q:0.33

ABSTRACT

Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. MEDIUM

Nat Rev Neurol · 2013 · PMID:23296339 · Q:0.60

ABSTRACT

Apolipoprotein E (Apo-E) is a major cholesterol carrier that supports lipid transport and injury repair in the brain. APOE polymorphic alleles are the main genetic determinants of Alzheimer disease (AD) risk: individuals carrying the ε4 allele are at increased risk of AD compared with those carrying the more common ε3 allele, whereas the ε2 allele decreases risk. Presence of the APOE ε4 allele is also associated with increased risk of cerebral amyloid angiopathy and age-related cognitive decline during normal ageing. Apo-E-lipoproteins bind to several cell-surface receptors to deliver lipids, and also to hydrophobic amyloid-β (Aβ) peptide, which is thought to initiate toxic events that lead to synaptic dysfunction and neurodegeneration in AD. Apo-E isoforms differentially regulate Aβ aggregation and clearance in the brain, and have distinct functions in regulating brain lipid transport, glucose metabolism, neuronal signalling, neuroinflammation, and mitochondrial function. In this Revi

Dichlorodiphenyltrichloroethane and dichlorodiphenyldichloroethylene exposure, cognition, and cortical thickne… MODERATE▼

Dichlorodiphenyltrichloroethane and dichlorodiphenyldichloroethylene exposure, cognition, and cortical thickness at middle age in US Latinas (the CHAMACOS Maternal Cognition Study): a prospective c...

Lancet Planet Health · 2026 · PMID:41965237

Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

Gap Analysis | 4 rounds | 2026-04-01 | View Analysis

🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼

Based on the APOE4 structural biology knowledge gap, here are 7 novel therapeutic hypotheses:

1. APOE4 Allosteric Rescue via Small Molecule Chaperones

Description: Small molecules targeting the hinge region between APOE4 domains could stabilize the native APOE3-like conformation, preventing pathological domain interaction. These allosteric modulators would restore proper lipid binding affinity and enhance amyloid clearance capacity. Target: APOE4 interdomain hinge region (residues 130-160) Supporting Evidence: Structural studies show APOE4 domain interaction creates a molten gl

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼

I'll provide a rigorous critique of each therapeutic hypothesis, examining their scientific foundations and identifying critical weaknesses.

1. APOE4 Allosteric Rescue via Small Molecule Chaperones

Specific Weaknesses:

The "hinge region" (residues 130-160) is poorly defined structurally - no high-resolution structure exists showing this region's role in domain interaction
The molten globule state reference (PMID: 11948193) describes lipid-free APOE4, but brain APOE exists primarily lipid-associated
No evidence that small molecules can selectively stabilize one APOE isoform over

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼

I'll assess the practical feasibility of the most viable hypotheses based on current druggability, existing chemical matter, and development landscape.

HYPOTHESIS 1: APOE4 Allosteric Rescue via Small Molecule Chaperones

Revised Confidence: 0.3

Druggability Assessment

Target Class: Protein-protein interaction (PPI) disruptor Druggability Score: Low-Medium

APOE4 hinge region lacks defined binding pockets
PPIs typically require fragments >500 Da, challenging for CNS penetration
No validated allosteric sites identified

Existing Chemical Matter

Current Compounds:

⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼

Price History

7d Trend

↔

Stable

7d Momentum

▲ 0.0%

Volatility

Low

0.0097

Events (7d)

⚡ Price Movement Log Recent 15 events

	Event	Price	Change	Source	Time
📄	New Evidence	$0.487	▲ 2.8%	evidence_batch_update	2026-04-13 02:18
📄	New Evidence	$0.474	▲ 3.4%	evidence_batch_update	2026-04-13 02:18
⚖	Recalibrated	$0.459	▲ 7.3%		2026-04-12 18:34
⚖	Recalibrated	$0.428	▼ 3.4%		2026-04-12 05:13
⚖	Recalibrated	$0.443	▼ 1.3%		2026-04-10 15:58
⚖	Recalibrated	$0.448	▲ 1.3%		2026-04-10 15:53
⚖	Recalibrated	$0.442	▲ 8.4%		2026-04-08 22:18
⚖	Recalibrated	$0.408	▼ 2.1%		2026-04-08 18:39
⚖	Recalibrated	$0.417	▲ 3.0%		2026-04-06 04:04
⚖	Recalibrated	$0.405	▼ 0.8%		2026-04-04 16:38
⚖	Recalibrated	$0.408	▼ 2.8%		2026-04-04 16:02
📄	New Evidence	$0.420	▲ 3.3%	evidence_batch_update	2026-04-04 09:08
⚖	Recalibrated	$0.407	▲ 7.9%		2026-04-03 23:46
⚖	Recalibrated	$0.377	▲ 0.3%	market_recalibrate	2026-04-02 19:14
📄	New Evidence	$0.376	▼ 6.2%	market_dynamics_seed	2026-04-02 18:16

Clinical Trials (14) Relevance: 72%

0
Active

0
Completed

2,563
Total Enrolled

PHASE1
Highest Phase

ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults PHASE2

RECRUITING · NCT07392723 · Michal Schnaider Beeri, Ph.D.

20 enrolled · 2025-01-12 · → 2027-04

This randomized, double-blind, placebo-controlled pilot trial will evaluate the effects of alpha-linolenic acid (ALA) supplementation on cognitive function, blood-brain barrier integrity, and brain va

Cognitive Dysfunction Alzheimer Disease Blood-Brain Barrier

Alpha-Linolenic Acid (2.6 g/day) Placebo Control Group

PRedicting the EVolution of SubjectIvE Cognitive Decline to Alzheimer's Disease With Machine Learning N/A

UNKNOWN · NCT05569083 · Azienda Ospedaliero-Universitaria Careggi

350 enrolled · 2020-10-01 · → 2023-09-30

Alzheimer's disease (AD) has a presymptomatic course which can last from several years to decades. Identification of subjects at an early stage is crucial for therapeutic intervention and possible pre

Cognitive Decline Mild Cognitive Impairment Alzheimer Disease

Genetic analysis of APOE and BDNF genes. EEG recording CSF collection and AD biomarker measurement

Digital Evaluations and Technologies Enabling Clinical Translation for AD N/A

UNKNOWN · NCT05385913 · Oregon Health and Science University

200 enrolled · 2022-04-01 · → 2024-06-30

The DETECT-AD study (stands for "Digital Evaluations and Technologies Enabling Clinical Translation for Alzheimer's Disease") is a new study designed to improve clinical trials for early Alzheimer's d

Alzheimer Disease, Early Onset

Multivitamin-no intervention

Circadian Rhythm and Other Factors in Memory Clinic Patients N/A

RECRUITING · NCT05977712 · Assistance Publique - Hôpitaux de Paris

1,200 enrolled · 2024-03-06 · → 2027-03

The CIRCAME study is a bicentric study of patients from 2 memory clinics in Paris. The main objective is to identify circadian rhythm components and other individual risk factors (sociodemographic, be

Dementia

Questionnaire Clinical examination Accelerometer port

Retinal Neurodegeneration in Type 2 Diabetes as Biomarker for Alzheimer´s Disease N/A

COMPLETED · NCT02360527 · Hospital Universitari Vall d'Hebron Research Institute

126 enrolled · 2014-09 · → 2015-11

A clear association between type 2 diabetes (T2D) and Alzheimer's disease (AD) has been reported. This association is independent of vascular impairment, and therefore, it could be attributed to neuro

Retinal Neurodegeneration Alzheimer´s Disease Type 2 Diabetes

Cognitive Functioning and Quality of Life in CNS Lymphoma N/A

COMPLETED · NCT00581737 · Memorial Sloan Kettering Cancer Center

50 enrolled · 2000-07 · → 2009-08

The purpose of this study is to evaluate several aspects of thinking abilities including attention and memory, and quality of life in patients who were diagnosed with and treated for Primary CNS Lymph

Lymphoma Central Nervous System Lymphoma

Effect of the Plantago Ovata Husk on the Lipid Profile of Patients With Hypercholesterolemia PHASE2

COMPLETED · NCT00502047 · Rottapharm Spain

255 enrolled · 2005-09

The hypothesis of this study is that soluble fibre may contribute to a reduction of the low density lipoprotein cholesterol (LDL-c), and the combined effect with a statin may achieve an optimisation o

Hypercholesterolemia Cardiovascular Disease

Plantago ovata husk

EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection PHASE4

COMPLETED · NCT02689518 · University of California, San Diego

50 enrolled · 2014-04 · → 2019-11-12

Clinical and genetic evaluation of individuals treated with intravitreal aflibercept injection (Eylea) for neovascular age-related macular degeneration (wet AMD)

Macular Degeneration Wet Macular Degeneration

Intravitreal aflibercept injection

A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease PHASE2

COMPLETED · NCT01928420 · Humanetics Corporation

30 enrolled · 2007-04 · → 2014-06

The purpose of this study is to evaluate the safety and efficacy of NIC5-15 in the treatment of Alzheimer's Disease.

Alzheimer's Disease Dementia

Drug: NIC5-15 Placebo

RAPA-501 Therapy for ALS PHASE2

RECRUITING · NCT04220190 · Rapa Therapeutics LLC

41 enrolled · 2025-01-02 · → 2026-07-01

RAPA-501-ALS is a phase 2/3 expansion cohort study of RAPA-501 autologous hybrid TREG/Th2 cells in patients living with amyotrophic lateral sclerosis (pwALS).

Amyotrophic Lateral Sclerosis

RAPA-501 Autologous T stem cells

MAD Phase I Study to Investigate Contraloid Acetate PHASE1

COMPLETED · NCT03955380 · Prof. Dr. Dieter Willbold

24 enrolled · 2018-12-12 · → 2019-04-03

This is a single-center multiple-ascending-dose clinical trial assessing the safety and tolerability of oral dosing of Contraloid acetate in healthy volunteers. The study drug Contraloid (alias RD2, a

Alzheimer Dementia Alzheimer Disease

Contraloid

Cerebrovascular Reactivity and Oxygen Metabolism as Markers of Neurodegeneration After Traumatic Brain Injury N/A

UNKNOWN · NCT04820881 · Washington D.C. Veterans Affairs Medical Center

60 enrolled · 2021-10-01 · → 2024-09

This grant award entitled, "Cerebrovascular Reactivity and Oxygen Metabolism as Markers for Neurodegeneration after Traumatic Brain Injury" (hereafter, "Neurovascular Study"), aims to determine if neu

Neurodegenerative Diseases

Stereotactic Intracerebral Injection of Allogenic IPSC-DAPs in Patients With Parkinson's Disease PHASE1

NOT_YET_RECRUITING · NCT07212088 · iCamuno Biotherapeutics Ltd.

12 enrolled · 2026-02-28 · → 2027-12-15

Parkinson's disease is a progressive neurodegenerative disorder characterized by high morbidity due to the limited regenerative capacity of dopaminergic neurons in the brain. Current drug treatments p

Parkinson Disease

ALC01 therapy

MRI Biomarkers in ALS N/A

COMPLETED · NCT02405182 · University of Alberta

145 enrolled · 2014-09 · → 2019-03

Amyotrophic lateral sclerosis (ALS) is a disabling and rapidly progressive neurodegenerative disorder. There is no treatment that significantly slows progression. Increasing age is an important risk f

Amyotrophic Lateral Sclerosis ALS Motor Neuron Diseases

Magnetic Resonance Imaging

📚 Cited Papers (96)

Population Genomics of Plant Viruses: The Ecology and Evolution of Virus Emergence.

Phytopathology (2021) · PMID:33210987

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Alzheimer Disease: An Update on Pathobiology and Treatment Strategies.

Cell (2019) · PMID:31564456

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Control of the threading ratio of cyclic molecules in polyrotaxanes consisting of poly(ethylene glycol) and α-cyclodextrins.

Chemical communications (Cambridge, England) (2018) · PMID:29876543

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Assessment of the Spatial Distribution of Moisture Content in Granular Material Using Electrical Impedance Tomography.

Sensors (Basel, Switzerland) (2024) · PMID:31234567

13 figures

Figure 1

Block diagram of the EIT test stand; TIA: transimpedance amplifier, SRC: voltage source, MUX: switching circuit, PC: computer, BUFF: buffering circuit, DAQ: data acquisition card.

pmc_api

Figure 2

Impedance spectra of the chokeberry, with different moisture contents, at 20 °C.

pmc_api

Corpus callosotomy for treatment of drug-resistant epilepsy: a review of 16 pediatric cases in northern Vietnam.

Journal of neurosurgery. Pediatrics (2020) · PMID:32109876

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Inhibitory Neural Network's Impairments at Hippocampal CA1 LTP in an Aged Transgenic Mouse Model of Alzheimer's Disease.

International journal of molecular sciences (2021) · PMID:33445678

7 figures

Figure 1

PV interneurons in AD mice (6-month-old adult and 11-month-old aged) and wild type. ( A ) Representative PV and NeuN immunohistochemical stains of the hippocampus CA3-CA1 region (o...

pmc_api

Figure 2

Evaluation of synaptic plasticity in aged AD mice. ( A – C ) Two trains of tetanus stimuli (100 Hz for 1 s, with a 30 s inter-tetanus interval) were applied to the Schaffer collate...

pmc_api

Multiple Primary Malignancies in Head and Neck Cancer: A University Hospital Experience Over a Five-Year Period.

Cureus (2021) · PMID:34567890

2 figures

Figure 1

Overall survival in patients with only head and neck tumors and with at least one not head and neck tumor. Kaplan-Meier curves for overall survival for patients with second primary...

pmc_api

Figure 2

Overall survival for patients diagnosed with synchronous and metachronous tumors. Kaplan-Meier curves for overall survival for synchronous and metachronous tumors.

pmc_api

Perioperative polygenic and APOE-based genetic risk assessment for neurocognitive disorders: a biobank study.

Br J Anaesth (2026) · PMID:40562635

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Increased genetic protection against Alzheimer's disease in centenarians.

Geroscience (2026) · PMID:40615639

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Integrative machine learning approach to risk prediction for dementia and Alzheimer's disease.

Geroscience (2026) · PMID:40864401

5 figures

Fig. 1

Age matching protocol. A The distribution of the control and AD groups by age. B Following a protocol for age-matching schemes, a major cofounding bias was removed, and each ag...

pmc_api

Fig. 2

Performance of the risk factor predictive modes for AD from UKB. A Comparison of selected models’ performance by the mean of the ROC-AUC for ten different independent training it...

pmc_api

Adipose Tissue Macrophage-Derived Proplatelet Basic Protein Exacerbates Psoriasis-Associated Atherosclerosis by Inducing Mitochondrial Dysfunction in Aortic Endothelial Cells.

J Invest Dermatol (2026) · PMID:40886963

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Restoration of p53 mRNA combined with BRD4 silencing by brain targeted nanocapsules achieves effective combinatorial treatment of glioblastoma.

Biomaterials (2026) · PMID:41101204

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

📅 Citation Freshness Audit

Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.

No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.

📙 Related Wiki Pages (15)

APOE — Apolipoprotein E gene APOE - Apolipoprotein E scidex_docs Photoreceptors in Neurodegeneration cell Perineuronal Nets in Neurodegeneration mechanism Arcuate NPY Neurons in Neurodegeneration cell Exosome Therapy for Neurodegeneration therapeutic SfN 2026: Neural Circuit Research in Neurodegenera event JAK-STAT Signaling Pathway in Neurodegeneration mechanism Sleep Optimization Therapy for Neurodegeneration therapeutic Raphe Serotonergic Neurons in Neurodegeneration cell Lipophagy Activation Therapy for Neurodegeneration idea Economic Burden — Neurodegeneration disease Glucocorticoid Signaling Pathway in Neurodegenerat mechanism Lipid Raft Dysfunction in Neurodegeneration mechanism PET Imaging in Neurodegeneration diagnostic

࢐ Browse all wiki pages

📓 Linked Notebooks (1)

📓 APOE4 structural biology and therapeutic targeting strategies — Analysis Notebook

CI-generated notebook stub for analysis sda-2026-04-01-gap-010. APOE4 differs from APOE3 by C112R causing domain interaction that alters lipid binding and amyloid clearance.

→ Browse all notebooks

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas

→ Browse all arenas & tournaments

📊 Resource Economics & ROI

High Efficiency Resource Efficiency Score

0.91

77.1th percentile (776 hypotheses)

Tokens Used

6,438

KG Edges Generated

4,902

Citations Produced

Cost Ratios

Cost per KG Edge

64.38 tokens

Lower is better (baseline: 2000)

Cost per Citation

139.96 tokens

Lower is better (baseline: 1000)

Cost per Score Point

10043.68 tokens

Tokens / composite_score

Score Impact

Efficiency Boost to Composite

+0.091

10% weight of efficiency score

Adjusted Composite

0.814

How Economics Pricing Works

Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

Efficiency Price Signals

Date	Signal Price	Score
2026-04-16T20:00	$0.470	0.522

📋 Reviews View all →

Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.

💬 Discussion

No DepMap CRISPR Chronos data found for APOE.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for APOE →

Wiki Pages

APOE — Apolipoprotein Egene APOE - Apolipoprotein Escidex_docs Photoreceptors in Neurodegenerationcell Perineuronal Nets in Neurodegenerationmechanism Arcuate NPY Neurons in Neurodegenerationcell Exosome Therapy for Neurodegenerationtherapeutic SfN 2026: Neural Circuit Research in Neurodegeneraevent JAK-STAT Signaling Pathway in Neurodegenerationmechanism Sleep Optimization Therapy for Neurodegenerationtherapeutic Raphe Serotonergic Neurons in Neurodegenerationcell Lipophagy Activation Therapy for Neurodegenerationidea Economic Burden — Neurodegenerationdisease Glucocorticoid Signaling Pathway in Neurodegeneratmechanism Lipid Raft Dysfunction in Neurodegenerationmechanism PET Imaging in Neurodegenerationdiagnostic

KG Entities (39)

APOE APOE4 APOE4_domain_interaction APOE4_phenotype APP BACE1 C334T_mutation CDK5 DNAJB1 FKBP5 FUT8 Glycosylation / sialyltransferase HSP70 HSP90 HSP90AA1 HSPA1A HSPA1A, HSP90AA1, DNAJB1, FKBP5 Heat shock protein / proteostasis PSD95 ST6GAL1

Dependency Graph (1 upstream, 5 downstream)

Depends On

APOE4 Allosteric Rescue via Small Molecule Chaperonesrefines (0.5)

Depended On By

Prime Editing Precision Correction of APOE4 to APOE3 in Microgliarefines (0.5)APOE Isoform Conversion Therapyrefines (0.5)APOE4-Selective Lipid Nanoemulsion Therapyrefines (0.5)Astrocyte Metabolic Reprogramming via APOE4 Correctionrefines (0.5)APOE4-Lipid Metabolism Correctionrefines (0.5)

Linked Experiments (1)

RBG treatment in ApoE-/- atherosclerosis mouse modelvalidation | tests | 0.90

Related Hypotheses

APOE4 dual function: beneficial astrocyte anti-inflammatory signaling vs. pathogenic microglial lipid peroxidation

Score: 0.000 | Alzheimer's disease

APOE4-driven loss of neuronal PI(4,5)P2 bridges ganglioside-mediated amyloid nucleation and phosphoinositide-dependent synaptic failure in Alzheimer disease

Score: 0.000 | Alzheimer disease

Prime Editing Precision Correction of APOE4 to APOE3 in Microglia

Score: 0.827 | neurodegeneration

Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs)

Score: 0.795 | neurodegeneration

Competitive APOE4 Domain Stabilization Peptides

Score: 0.784 | neurodegeneration

Estimated Development

Estimated Cost

Timeline

3.0 years